Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 4/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.37 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738113 | 1.00 | P4HB (0.48) | P4HBTRPV4NFKB1ITGB3ITGAV | |
| SCHEMBL12154395 | 0.81 | P4HB (0.43) | P4HBTRPV4NFKB1MRGPRX4MAOB | |
| SCHEMBL6708257 | 0.80 | MIF (0.61) | P4HBNFKB1MIFPIN1RAD51 | |
| SCHEMBL6708260 | 0.80 | MIF (0.61) | P4HBNFKB1MIFPIN1RAD51 | |
| SCHEMBL4668561 | 0.78 | CA1 (0.51) | P4HBNFKB1MIFAPPPIN1 | |
| SCHEMBL6046317 | 0.78 | MIF (0.63) | P4HBNFKB1ITGB3ITGAVITGA2B | |
| SCHEMBL4783571 | 0.78 | CES2 (0.50) | NFKB1ITGB3ITGAVITGA2BMIF | |
| SCHEMBL6046318 | 0.78 | MIF (0.63) | P4HBNFKB1ITGB3ITGAVITGA2B | |
| SCHEMBL1950609 | 0.78 | TDO2 (0.51) | P4HBNFKB1ITGB3ITGAVITGA2B | |
| SCHEMBL1950607 | 0.78 | TDO2 (0.51) | P4HBNFKB1ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2390252-A1 | New pyrazole derivatives | Almirall, S.A. (ES) | 2011-11-30 | — | — | EP | disclosed |
| WO-2011144338-A1 | PYRAZOLE DERIVATIVES AS S1P1 AGONISTS | ALMIRALL, S.A. (ES) | 2011-11-24 | — | — | WO | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | P4HB 3789/4885TRPV4 518/4885NFKB1 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.